Terns Pharmaceuticals Files 8-K

TL;DR

Terns Pharma filed an 8-K, but the details are in the full doc.

AI Summary

Terns Pharmaceuticals, Inc. filed an 8-K on September 9, 2024, reporting on other events and financial statements. The filing does not contain specific details about new agreements, material events, or financial figures within the provided text.

Why It Matters

This filing indicates Terns Pharmaceuticals is making a regulatory disclosure, but the specific nature of the event is not detailed in the provided excerpt.

Risk Assessment

Risk Level: low — The filing is a standard procedural disclosure without immediate negative or positive financial implications mentioned.

Key Players & Entities

• Terns Pharmaceuticals, Inc. (company) — Registrant
• September 09, 2024 (date) — Date of earliest event reported
• Delaware (jurisdiction) — State of Incorporation
• 001-39926 (identifier) — Commission File Number
• 98-1448275 (identifier) — IRS Employer Identification No.
• 1065 East Hillsdale Blvd. Suite 100 (address) — Principal Executive Offices
• Foster City, California (location) — Principal Executive Offices Location
• 94404 (zip_code) — Principal Executive Offices Zip Code
• (650) 525-5535 (phone_number) — Registrant's Telephone Number

FAQ

Key Financial Figures

• $0.0001 — nge on which registered Common Stock, $0.0001 par value per share TERN Nasdaq Glo

Filing Documents

• tern-20240909.htm (8-K) — 69KB
• tern-ex99_1.htm (EX-99.1) — 47KB
• 0000950170-24-104550.txt ( ) — 247KB
• tern-20240909.xsd (EX-101.SCH) — 26KB
• tern-20240909_htm.xml (XML) — 5KB

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. On September 9, 2024, Terns Pharmaceuticals, Inc. (the "Company" or "Terns") issued a press release announcing positive top-line data from its Phase 1 randomized, double-blind, placebo-controlled single and multiple-ascending dose (SAD and MAD) trial to assess the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of TERN-601 dosed once-daily (QD) in healthy adults with obesity or overweight . A copy of the press release is attached to this Current Report on Form 8-K as Exhibit 99.1. The information contained in Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

01 Other Events

Item 8.01 Other Events. On September 9, 2024, Terns announced positive top-line data from its Phase 1 randomized, double-blind, placebo-controlled SAD/MAD trial to assess the safety, tolerability, PK and PD of TERN-601 QD in healthy adults with obesity or overweight. The clinical trial results showed TERN-601 was well tolerated and demonstrated dose-dependent, statistically significant placebo-adjusted mean weight loss across all three doses evaluated in the 28-day MAD study, with maximum placebo-adjusted mean weight loss of 4.9% (p<0.0001) at the highest dose of 740 mg QD. Additionally, 67% of participants lost 5% or more of their baseline body weight at the top dose. Terns believes these data support the potential of TERN-601 for the treatment of obesity as monotherapy or in combination with agents such as TERN-501, the Company's internally discovered, clinical stage THR- agonist, or a GIPR modulator from the Company's TERN-800 series. Terns anticipates advancing TERN-601 into Phase 2 clinical development in 2025. Terns believes it has successfully identified an optimal range of clinically active, well tolerated doses to take forward in Phase 2 clinical trials, with no new dose range exploration anticipated. Table 1: Mean Percent Weight Change from Baseline to Day 28 Placebo (N=9) TERN-601 240 mg (N=9) TERN-601 500 mg (N=9) TERN-601 740 mg (N=9) % weight change from baseline -0.6% -2.5% -4.4% -5.5% % weight change placebo-adjusted (90% CI) - -1.9% -3.8% -4.9% Exploratory p-value vs. placebo - <0.1 <0.01 <0.0001 TERN-601 was well tolerated with no treatment-related dose interruptions, reductions or discontinuations at any dose, despite fast titration to high doses . The majority (>95%) of treatment emergent adverse events (AEs) were mild. All gastrointestinal AEs were mild to moderate and consistent with the GLP-1R agonist class. Importantly, there were no clinically meaningful changes in liver enzymes, vital signs

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release issued by Terns Pharmaceuticals, Inc. on September 9, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. TERNS PHARMACEUTICALS, INC. Date: September 9, 2024 By: /s/ Elona Kogan Elona Kogan Chief Legal Officer

View Full Filing

View this 8-K filing on SEC EDGAR